Guanhao Biotech Co.,Ltd. announced that it expects to receive CNY 500 million in funding from Beijing Century Tianfu Venture Capital Center (Limited Partnership), Beijing Tianyou Investment Co., Ltd., Jiangsu Tianyou Jingan Investment Co., Ltd.
March 21, 2023
Share
Guanhao Biotech Co.,Ltd. entered into a share subscription agreement for the placement of not more than 55,803,571 A shares at an issue price of CNY 8.96 per share for gross proceeds of not more than CNY 500,000,000 on March 22, 2023. The transaction will include participation from Beijing Century Tianfu Venture Capital Center (Limited Partnership), Beijing Tianyou Investment Co., Ltd. and Jiangsu Tianyou Jingan Investment Co., Ltd. The shares issued shall not be transferred within 36 months from the date of completion of this issuance. The transaction has been approved at the 15th meeting of the company's fifth board of directors and still needs to be reviewed and approved by the company's shareholders' meeting, Shenzhen Stock Exchange and China Securities Regulatory Commission.
Guanhao Biotech Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of regeneration medical materials and medical implanted devices. The Company primarily provides biological dura mater patches, chest general surgery department patching membranes (type P) and (type B), asepsis biological wound-surface protection membranes, type B dura matrix, intraocular lens as well as agent products. The Company is also engaged in provision of related technological services.
Guanhao Biotech Co.,Ltd. announced that it expects to receive CNY 500 million in funding from Beijing Century Tianfu Venture Capital Center (Limited Partnership), Beijing Tianyou Investment Co., Ltd., Jiangsu Tianyou Jingan Investment Co., Ltd.